Researchers found that nearly 15% of commercially insured PrEP users had an alcohol use disorder diagnosis, yet fewer than 9% received FDA-approved treatment.
After showing higher efficacy and a comparable safety profile to Spikevax, the FDA has approved Moderna’s mNEXSPIKE COVID-19 vaccine for high-risk patients.
A MAHA commission report on child health cited several studies that could not be verified, leading to corrections and questions about sourcing accuracy.
The FDA has approved Khindivi, the first hydrocortisone oral solution for pediatric adrenal insufficiency, offering precise, ready-to-use dosing for patients aged 5 years and older.